Table 2.
Baseline patient demographics and characteristics and AT9283 treatment cycles
| Characteristic | AT9283 dose (mg/m2) | All (N=48) | ||
|---|---|---|---|---|
| Part A (72h infusion) | Part B | |||
| 9 – 486 (n=32) | 160a (n=12) | 200b (n=4) | ||
| Median age (y, range) | 61.5 (22–86) | 61.5 (31–78) | 57.5 (53–68) | 61 (22–86) |
| Male, n (%) | 16 (50) | 8 (67) | 3 (75) | 27 (56) |
| Diagnosis, n (%) | ||||
| ALL | 1 (33) | 0 | 0 | 1 (2) |
| AML | 24 (75) | 9 (75) | 3 (75) | 36 (75) |
| CML | 2 (6) | 0 | 0 | 2 (4) |
| MMM (I) | 1 (3) | 2 (17) | 1 (25) | 4 (8) |
| MMM (II) | 4 (13) | 1 (8) | 0 | 5 (10) |
| Number of prior lines of therapy, n (%) | ||||
| 1 | 3 (10) c | 0 | 0 | 3 (7) c |
| 2 | 2 (6) c | 0 | 0 | 2 (4) c |
| ≥3 | 26 (84) c | 10 (100) c | 4 (100) | 40 (89) c |
| Best response to most recent therapy, n (%) | ||||
| - Complete remission | 2 (6) c | 0 | 0 | 2 (4) c |
| - Disease progression | 8 (26) c | 3 (30) c | 4 (100) | 15 (33) c |
| - Disease transformation | 1 (3) c | 0 | 0 | 1 (2) c |
| - Failure | 15 (48) c | 3 (30) | 0 | 18 (40) c |
| - Relapse after complete or partial remission | 2 (6) c | 0 | 0 | 2 (4) c |
| - Stable disease | 2 (6) c | 1 (10) c | 0 | 3 (7) c |
| - Unknown | 1 (3) c | 3 (30) c | 0 | 4 (9) c |
| Previous chemotherapy or leukemia, n (%) | ||||
| Yes | 4 (13) | 2 (17) | 1 (25) | 7 (15) |
| No | 28 (88) | 10 (83) | 3 (75) | 41 (85) |
| Number of AT9283 cycles received, n (%) | ||||
| ≥1 | 32 (100) | 12 (100) | 4 (100) | 48 (100) |
| ≥2 | 15 (47) | 3 (25) | 0 | 18 (38) |
| ≥3 | 4 (13) | 1 (8) | 0 | 5 (10) |
| ≥4 | 1 (3) | 0 | 0 | 1 (2) |
| ≥5 | 1 (3) | 0 | 0 | 1 (2) |
| ≥6 | 1 (3) | 0 | 0 | 1 (2) |
a
96 hr infusion (includes 2 cohorts)
b
120 hr infusion
c
Percentage calculated based on available data (5 of 6 patients in the 324 mg/m2 group [i.e., 31 of 32 patients in Part A] and 10 of 12 patients in the 160 mg/m2 group)